Buy-and-bill economics: the launch-quarter reimbursement gap nobody mentions

A health system evaluating a newly launched, physician-administered drug is not just asking whether it works. Somewhere in that review, usually in the finance section, someone is asking a quieter question: what does this actually pay, and does that change in six months? For a drug reimbursed under buy-and-bill, the honest answer is that it gets paid differently at launch than it will once the drug has been on the market a year, and the reason is structural, not political.

Why launch-quarter reimbursement is different

Most physician-administered drugs under Medicare Part B are reimbursed against Average Sales Price, commonly called ASP. ASP is calculated from a manufacturer's actual sales data, reported quarterly, and CMS uses that data to set payment limits with a built-in reporting lag of a couple of quarters. That system works well once a drug has an actual sales history to calculate ASP from.

A drug at launch does not have one. There is no prior quarter of sales to report, so there is no ASP yet. During that window, Medicare pays based on the drug's Wholesale Acquisition Cost, WAC, instead, using a different, lower add-on than the ASP-based formula. Only after real sales data accumulates, typically a couple of quarters in, does the drug transition to ASP-based payment, and even then it is paying against sales data that is already a quarter or two old. The launch window and the steady-state window are not the same economic environment. Treating them as if they were is exactly what leads to confusion later.

What this means on the ground

A health system's acquisition cost for a new drug does not automatically track whatever CMS or a commercial payer happens to be reimbursing that quarter. WAC is a list price set by the manufacturer, and it is not designed to mirror a payment formula built around sales data that does not exist yet. Depending on where WAC is set relative to eventual ASP, and how utilization and any early discounting evolve, the launch-quarter margin on a drug can run more favorable or less favorable than the margin a year later, and it is genuinely hard to know which in advance.

Commercial payers complicate this further. Many contract using a percentage of ASP as the benchmark, which means a payer's fee schedule inherits the same lag and the same launch-window uncertainty that Medicare has, on top of whatever the individual payer's own timing and update cycle adds.

None of this is a reason to avoid a good drug. It is a reason finance and pharmacy leadership ask about reimbursement timing specifically, and it is exactly the kind of question that shows up in the formulary review process I have described elsewhere: what does this cost at expected volume, and what happens if that gap runs the wrong way for two or three quarters before it settles.

Why this matters for a field conversation

• A site that seems slow to commit volume at launch may simply be waiting for the reimbursement picture to stabilize, not expressing doubt about the product.
• A finance team asking pointed questions about margin at three months post-launch is not being difficult. They are asking a specific, structural question that has a specific, structural answer, and being able to speak to it plainly is worth more than reassurance.
• The site-of-care conversation gets sharper here too. A hospital outpatient department, a physician office, and a 340B-eligible site can each see a different effective margin on the same drug in the same quarter, for reasons that have nothing to do with clinical fit.
• Biosimilar and interchange timing interacts with this directly. A conversion decision made purely on ASP trend can look very different once the launch-window distortion in the comparator's own history is accounted for.

What I actually do with this

This is the kind of reimbursement mechanic I walk field and market access teams through under provider-side reimbursement and coverage education: not the statutory detail for its own sake, but what it means for the specific conversation you are about to have with a specific health system, and how to answer the margin question in the room instead of promising to follow up.

The rates and formulas move. CMS updates payment limits quarterly, and sequestration and other adjustments have shifted the add-on percentages more than once over the years, so I have deliberately left exact figures out of this piece rather than publish a number that will be wrong by the time someone reads it. The structure underneath, launch on WAC, transition to lagged ASP, has held for years and is the part actually worth understanding.

Robert Walters, PharmD, MBA is the founder of Walters Rx Strategy and is Apexus Advanced 340B Certified. He spent fifteen years leading health-system pharmacy operations across acute care, a cancer center, infusion, and emergency department pharmacy. Book a consult or read more insights.

This article is general and informational. It is not legal, regulatory, financial, clinical, or medical advice, and it does not recommend or promote any specific product or therapy.